Ulrik Spork
Chairman of the board
Board member since: 2024
Born: 1964
Holdings in Spermosens
–
Ulrik Spork has a strong background in institutional investments and has held positions as Managing Partner and Senior Partner at Novo Holdings. His responsibilities have included overseeing Principal Investments, Novo Growth Equity, and Novo Ventures. Since 2016, he has served as chairman of Danish Growth Capital II. In addition to venture investments, Ulrik also has extensive experience with SME boards in the medical technology and life science sectors and has over the last 30 years served as chairman or board member in more than 30 startup companies in jurisdictions across North America, Europe and Scandinavia.
Other ongoing significant assignments: Chairman in SoftOx Solutions AS, Innocon Medical ApS, board member in Cerebriu ApS.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Ingela Liljeqvist Soltic
Board member
Board member since: 2019
Born: 1967
Holdings in Spermosens
–
Dr. Ingela Liljeqvist Soltic is currently working as an embryologist and unit manager for the laboratory and tissue establishment at the Reproductive Medicine Center (RMC) at Skåne University Hospital. Ingela holds a BSc in Biomedical Laboratory Technology from Lund University and a PhD in Biomedical Science. She has previously worked as an embryologist at the IVF Clinic Cura Öresund and at the pharmaceutical company Merck. Ingela has extensive experience in IVF and fertility issues.
Other ongoing significant assignments: –
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Christina Östberg-Lloyd
Board member
Board member since: 2022
Born: 1961
Holdings in Spermosens
–
Christina Östberg Lloyd is currently the founder and CEO of Care & Communication AB, a consultant in Life Science with a focus on strategy and business management, leadership, communication, as well as medical and scientific affairs. She is also part of the management team at 2HealMedical, a healthcare company focused on women’s health, preconception, and infertility. Additionally, she serves as the chair of VILDA, a national network for women in top management within Life Science. Christina has 25 years of experience in big pharma, including roles at Ferring and Novo Nordisk, and was also the CEO of the femtech company Pharmiva, which was publicly listed under her leadership. Until recently, she was the global head at Ferring Pharmaceuticals A/S, serving as Senior Vice President and Global Head of Reproductive Medicine Maternal Health, RMMH. Christina is an M.D. and a specialist in gynecology and obstetrics, with a focus on reproductive medicine, covering both male and female infertility.
Other ongoing significant assignments: –
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Søren Melsing Frederiksen
Board member
Board member since: 2020
Born: 1976
Holdings in Spermosens (through company and privately)
Shares: 395 132
Søren Melsing Frederiksen currently holds the position of CEO at Exocure Sweden AB. Søren has a B.Sc. in Applied Science and a Master’s degree in Pharmaceutical Development. He was previously VP of Commercial & Product Development at Orifarm; VP of Sales & Marketing at Galenica AB; Head of Commercial at Aspen Nordic, and prior to that, he held several positions at LEO Pharma. Søren has extensive experience in product development, marketing, sales, and the entire value chain in the pharmaceutical industry.
Other ongoing significant assignments: Board member of VBM Ejendomsselskabet af 2007 Aps and StenoCare A/S. Board member and CEO of SML Holding ApS.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Kushagr Punyani
Board member
Board member since: 2018
Born: 1991
Holdings in Spermosens (through company and privately)
Shares: 1 637 764
Kushagr Punyani is the founder of the Company and served as a CSO consultant for the company until March 2024. Kushagr holds a Licentiate degree in Engineering, specializing in microfluidic technology, from Lund University. From his studies in India, together with Professor Sudha Srivastava, Kushagr laid the foundation for the Company’s technology. He has also co-founded several companies developing new technologies in the medtech/pharmaceutical sectors.
Other ongoing significant assignments: Board member of Prolevi Bio AB and Diagonal Bio AB. Board member and CEO of Nested Bio AB.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
